![]() Daily. Med - VIVELLE DOT - estradiol patch, extended release. Vivelle- Dot. There may be new information. This information does not take the place of talking to your healthcare provider about your medical condition or your treatment. Vivelle- Dot is not for everyone. Talk to your healthcare provider if you have any questions or concerns about this medication. ![]() The estrogen patch (oestrogen patch) is a delivery system for estradiol, which is used as hormone replacement therapy to treat the problems of menopause, such as hot. Pictures of Vivelle-Dot (Estradiol Transdermal System), drug imprint information, side effects for the patient. Estradiol transdermal gel, patch, and spray are used to treat moderate to severe hot flashes and other symptoms of menopause or low amounts of estrogen. Multiple dosing options to fit your treatment needs. Estradiol Transdermal Patch: learn about side effects, dosage, special precautions, and more on MedlinePlus. Estradiol is a form of estrogen, a female sex hormone that's produced by the ovaries. Estradiol comes in an oral form, a transdermal skin patch, a vaginal ring, or as. What is Vivelle- Dot. When applied to the skin as directed below, Vivelle- Dot releases estrogen through the skin into the bloodstream. What is Vivelle- Dot used for? Vivelle- Dot is used after menopause to: Estrogens are hormones made by a woman. The ovaries normally stop making estrogens when a woman is between 4. This drop in body estrogen levels causes the . Sometimes, both ovaries are removed during an operation before natural menopause takes place. The sudden drop in estrogen levels causes . In some women, the symptoms are mild and they will not need estrogens. In other women, symptoms can be more severe. You and your healthcare provider should talk regularly about whether you still need treatment with Vivelle- Dot. You and your healthcare provider should talk regularly about whether you still need treatment with Vivelle- Dot to control these problems. If you use Vivelle- Dot only to treat your dryness, itching, and burning in and around your vagina, talk with your healthcare provider about whether a topical vaginal product would be better for you. Vivelle Dot, which is better for uses like: HRT, Hot Flashes and Night Sweats. Compare head-to-head ratings, side effects, warnings, dosages. Find patient medical information for Vivelle-Dot transdermal on WebMD including its uses, side effects and safety, interactions, pictures, warnings and user ratings. ![]() If you use Vivelle- Dot only to prevent osteoporosis from menopause, talk with your healthcare provider about whether a different treatment or medicine without estrogens might be better for you. You and your healthcare provider should talk regularly about whether you should continue with Vivelle- Dot. It is important to talk about exercise and supplements with your healthcare provider before starting them. Who should not take Vivelle- Dot? Do not start taking Vivelle- Dot if you: Tell your healthcare provider: How should I take Vivelle- Dot? Start at the lowest dose and talk to your healthcare provider about how well that dose is working for you. Estrogens should be used at the lowest dose possible for your treatment, only as long as needed. The lowest effective dose of Vivelle- Dot has not been determined for any indication. You and your healthcare provider should talk regularly (for example, every 3 to 6 months) about the dose you are taking and whether you still need treatment with Vivelle- Dot. Application Instructions for Vivelle- Dot (estradiol transdermal system)1. If you have questions, talk to your healthcare provider or pharmacist. What can I do to lower my chances of a serious side effect with Vivelle- Dot? General information about safe and effective use of Vivelle- Dot. Medicines are sometimes prescribed for conditions that are not mentioned in patient information leaflets. Do not take Vivelle- Dot for conditions for which it was not prescribed. Do not give Vivelle- Dot to other people, even if they have the same symptoms you have. Keep Vivelle- Dot out of the reach of children. If you would like more information, talk with your healthcare provider or pharmacist. You can ask for information about Vivelle- Dot that is written for health professionals. You can get more information by calling the toll- free number . Proceeding from the visible surface toward the surface attached to the skin, these layers are (1) a translucent polyolefin film (2) an adhesive formulation containing estradiol, acrylic adhesive, silicone adhesive, oleyl alcohol, NF, povidone, USP and dipropylene glycol, and (3) a polyester release liner which is attached to the adhesive surface and must be removed before the system can be used. The remaining components of the system are pharmacologically inactive. Other Information. Do not store above 2. Do not store outside of their pouches. Apply immediately upon removal from the protective pouch. T2. 00. 4- 6. 6REV: AUGUST 2. T2. 00. 4- 6. 5/T2. Manufactured by: Noven Pharmaceuticals Inc. Miami, FL 3. 31. 86. Distributed by: Novartis Pharmaceuticals Corporation. East Hanover, NJ 0. Vivelle- Dot (estradiol transdermal system) - Drug information from Medi. Lexicon. Company: Novartis. Approval Status: Approved May 2. Treatment for: Post- menopausal osteoporosis. Areas: Musculoskeletal; Pregnancy & Gynecology. This estrogen replacement therapy is currently marketed for the treatment of menopausal symptoms. Vivelle- Dot is a smaller, revised version of the original Vivelle transdermal product, which was approved in 2. The product utilizes Noven's DOT Matrix transdermal drug delivery technology to effectively deliver the drug through the small patch surface area. DOT Matrix patches use ratios of silicone, acrylic and drug to regulate the rate of delivery through the skin and into the bloodstream. With the approval for post- menopausal osteoporosis, Vivelle- Dot is now available in five dosage strengths: 0. The new 0. 0. 25. Clinical Results. Note: Vivelle- Dot was shown to be bioequivalent to Vivelle, the original formulation. The effectiveness of Vivelle for the prevention of post- menopausal osteoporosis was evaluated in a two- year, double- blind, randomized, placebo- controlled, parallel- group study. One hundred ninety- four of the subjects were randomized to receive one of four doses of Vivelle (0. Over two years, the study systems were applied to the buttock or the abdomen twice a week. Two hundred thirty- two (8. Vivelle, 5. 9 receiving placebo) contributed data to the primary efficacy measurement: analysis of percent change from baseline in bone mineral density (BMD) of the AP lumbar spine. An increase in BMD of the AP lumbar spine was observed in all Vivelle dose groups; in contrast, a decrease in AP lumbar spine BMD was observed in subjects receiving placebo. All doses of Vivelle were significantly superior to placebo at all time points, with the exception of Vivelle 0. A secondary efficacy measurement in the trial was an analysis of percent change from baseline in femoral neck BMD. Results showed that all doses of Vivelle were significantly superior to the placebo at 2. Additionally, the highest dose of Vivelle was more effective than the placebo at all time points. Side Effects. Systemic adverse events reported with Vivelle in clinical trials include (but are not limited to) the following: Headache (3. Vivelle, 2. 8% for placebo)Breast tenderness (1. Vivelle, 0% for placebo)Fluid retention (2. Vivelle, 1. 9% for placebo)Back pain (9% for Vivelle, 6. Mechanism of Action. Estrogens are largely responsible for the development and maintenance of the female reproductive system and secondary sexual characteristics. Although circulating estrogens exist in a dynamic equilibrium of metabolic interconversions, estradiol is the principal intracellular human estrogen and is substantially more potent than its metabolites, estrone and estriol, at the receptor level. The primary source of estrogen in normally cycling adult women is the ovarian follicle, which secretes 7. Thus, estrone and the sulfate conjugated form, estrone sulfate, are the most abundant circulating estrogens in post- menopausal women. Estrogens act through binding to nuclear receptors in estrogen- responsive tissues. To date, two estrogen receptors have been identified. They vary in proportion from tissue to tissue. Estrogen replacement therapy acts to reduce the elevated levels of these hormones seen in post- menopausal women. The information provided here is for general educational purposes only and does not constitute medical or pharmaceutical advice which should be sought from qualified medical and pharmaceutical advisers.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. Archives
December 2016
Categories |